Leipzig-based biotechnology innovator Primogene GmbH has successfully closed a €4.1 million seed funding round to scale its production of complex bioactive molecules. The investment was led by prominent deep-tech investor High-Tech Gründerfonds (HTGF) and will fuel the expansion of the company's proprietary enzymatic platform. This technology enables the sustainable and cost-efficient manufacturing of biomolecules for diverse markets including infant nutrition, adult health, and pharmaceuticals.
Addressing a Critical Need in Nutrition
Inspired by nature's blueprint, Primogene focuses on replicating the benefits of breast milk, the gold standard for infant nutrition. This is especially crucial for the 13 million infants born prematurely worldwide each year, who have acute nutritional requirements for healthy development. Clinical evidence highlights the vital role of specific human milk oligosaccharides (HMOs), like disialyllacto-N-tetraose (DSLNT), in supporting their immune systems and cognitive growth.
A Breakthrough in Biomolecule Production
Primogene’s enzymatic platform represents a significant leap forward, solving the production challenges inherent in established fermentation-based methods. These traditional approaches are often capital-intensive and face biological limits on the complexity of molecules they can efficiently produce. Primogene’s technology overcomes these constraints, enabling the scalable synthesis of structurally complex molecules that are identical to their natural equivalents, such as DSLNT.
Expanding Applications Across the Lifespan
The utility of Primogene’s technology extends well beyond the realm of infant nutrition, offering benefits for health at every stage of life. The bioactive molecules produced can support gut health in adults, enhance cognitive function in seniors, and serve as advanced functional ingredients in personal care products. By managing its entire production process in Germany, the company also bolsters the European supply chain for critical pharmaceutical raw materials.
Fueling Growth and Strategic Partnerships
The new capital will be strategically deployed to expand the company's intellectual property portfolio, forge new partnerships, and significantly increase production capacities at its Leipzig facility. The round was supported by a strong syndicate of investors, including Technologiegründerfonds Sachsen (TGFS), better ventures, and Sächsische Beteiligungsgesellschaft (SBG). This financial backing will empower Primogene to accelerate its mission of making these vital ingredients accessible on an industrial scale.
Primogene has already demonstrated significant commercial momentum, with established partnerships in the personal care sector and its ingredients already on the market. The company's pharmaceutical-grade materials are also in advanced evaluation stages with potential customers, signaling strong industry interest. In parallel, research collaborations with the Fraunhofer Institute and neonatal clinics are underway to explore new applications and define clinical dosing for its HMOs.
This €4.1 million investment marks a pivotal moment for Primogene, providing the necessary resources to scale its operations and accelerate market entry. The funding validates the company's innovative enzymatic approach, which unlocks the potential of complex biomolecules previously too difficult to produce. With this support, Primogene is well-positioned to become a key supplier of high-value ingredients that support human health from infancy through seniority.